Translate this page into:
Technetium-99m Labeled Tropane Derivative: Uptake in a Pituitary Macroadenoma
Address for correspondence: Dr. Madhavi Tripathi, Department of Nuclear Medicine and Positron Emission Tomography, All India Institute of Medical Sciences, New Delhi - 110 029, India. E-mail: madhavi.dave.97@gmail.com
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Abstract
We present a case of suspected idiopathic Parkinson's disease in whom extrastriatal accumulation of Technetium-99m labeled tropane derivatives in a pituitary macroadenoma interfered with image quality and interpretation. Subsequent F-18 fluoro-dihydroxyphenylalanine positron emission tomography/computed tomography was useful to demonstrate the absence of presynaptic dopaminergic dysfunction.
Keywords
Fluoro-dihydroxyphenylalanine
Parkinson disease
pituitary macroadenoma
single-photon emission computed tomography/computed tomography
technetium-99m labeled tropane derivatives
A 55-year-old male presented with difficulty in walking, tremors of bilateral upper limbs, scanning speech, and urinary incontinence, for the past 2 years. He was a known case of pituitary macroadenoma (PM) and was referred to our department for dopamine transporter single-photon emission computed tomography (DAT SPECT) with the clinical suspicion of Parkinson's disease. Technetium-99m labeled tropane derivative (Tc-99m TRODAT) (20 mCi) was injected intravenously and SPECT/CT was done 4 h later. Evaluation of the cine image [Figure 1a] revealed intense focal tracer accumulation which corresponded to PM on the fused axial SPECT/CT images [Figure 1b], and on magnetic resonance imaging [Figure 1c]. As a result of this intense uptake in the macroadenoma, tracer binding in the basal ganglia was suboptimal and while the left basal ganglia showed normal binding, the right side was interpreted as normal only after a careful review of the transaxial images [Figure 1d]. To further confirm the absence of presynaptic dopaminergic dysfunction, we performed a F-18 fluoro-dihydroxyphenylalanine (FDOPA) positron emission tomography/computed tomography (PET/CT) which revealed normal tracer uptake in both basal ganglia [Figure 1e]. No accumulation of FDOPA was noted in the PM [Figure 1f]. The symptoms of the patient were subsequently attributed to the presence of cerebellar atrophy.
Tc-99m TRODAT ([2-[2-[3-(4-chlorophenyl)-8-methyl-8-azabicyclo [3,2,1]oct-2-yl] methyl](2-mercaptoethyl) -amino] ethyl] amino] ethanethiolato (3-)-N2, N2’, S2, S2’]oxo-[1R-(exo-exo)]) binds to the DAT and is used for the evaluation of presynaptic dopaminergic function in Parkinsonism.[1234] The extrastriatal uptake of TRODAT has been reported in PM, primary brain tumors, brain metastases, meningioma, osteoid tumor of clivus, intracranial tuberculoma, and subdural hematoma.[5678910111213] The possibility of extrastriatal accumulation of TRODAT interfering with image interpretation as in our case should be kept in mind, while planning TRODAT SPECT and alternative modalities like FDOPA PET with superior image quality and resolution should be resorted to at the outset. F-18 FDOPA is an analog of DOPA and serves as substrate for aromatic amino acid decarboxylase that converts dopa to dopamine. It can be used as an alternative for Tc-99m TRODAT,[14] especially when the symptom duration of Parkinson's is not too short.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
- Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J Med Chem. 1997;40:9-17.
- [Google Scholar]
- 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes. Nucl Med Commun. 2018;39:312-8.
- [Google Scholar]
- 99mTc-TRODAT-1 SPECT imaging in early and late onset Parkinson's disease. Asia Ocean J Nucl Med Biol. 2017;5:114-9.
- [Google Scholar]
- Pituitary macroadenoma on 99mTc-TRODAT-1 brain SPECT. Clin Nucl Med. 2014;39:e398-401.
- [Google Scholar]
- Increased 99mTc TRODAT-1 uptake in anaplastic oligodendroglioma. Clin Nucl Med. 2014;39:e104-5.
- [Google Scholar]
- Findings of cerebral metastasis demonstrated on tc-99m TRODAT-1 SPECT. Clin Nucl Med. 2010;35:107-8.
- [Google Scholar]
- An incidental finding of cerebral meningioma on 99mTc-TRODAT-1 dopamine transporter SPECT/CT. Clin Nucl Med. 2012;37:899-900.
- [Google Scholar]
- Extra-striatal uptake of 99mTc-TRODAT-1 in meningioma detected on SPECT/CT: Diagnostic clue or mere coincidence? Indian J Nucl Med. 2017;32:243-4.
- [Google Scholar]
- Incidental detection of probable meningioma in brain scintigraphy using 99mTc-TRODAT-1. Arq Neuropsiquiatr. 2017;75:258-9.
- [Google Scholar]
- Tc-99m TRODAT uptake in an osteoid tumor of clivus. Indian J Nucl Med. 2016;31:309-10.
- [Google Scholar]
- Incidental detection of intracranial tuberculomas on (99m) Tc-TRODAT-1 SPECT/CT. Clin Nucl Med. 2015;40:e321-2.
- [Google Scholar]
- Findings of subdural hematoma on tc-99m-TRODAT-1 SPECT. Clin Nucl Med. 2009;34:245-6.
- [Google Scholar]
- Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients. J Nucl Med. 2003;44:999-1005.
- [Google Scholar]